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Abstract
b-lactamase production has been sporadically reported in the emerging Kingella kingae pathogen but the phenomenon has not been studied
in-depth.We investigated the prevalence of b-lactamase production among K. kingae isolates from different geographical origins and genetically
characterized b-lactamase-producing strains. Seven hundred and seventy-eight isolates from Iceland, the USA, France, Israel, Spain and Canada
were screened forb-lactamase production and, if positive, were characterized by PFGE andMLST genotyping, aswell as rtxA, por, blaTEM and 16S
rRNA sequencing. b-lactamase was identiﬁed in invasive strains from Iceland (n = 4/14, 28.6%), the USA (n = 3/15, 20.0%) and Israel (n = 2/
190, 1.1%) and in carriage strains in the USA (n = 5/17, 29.4%) and Israel (n = 66/429, 15.4%). No French, Spanish or Canadian isolates were
b-lactamase producers. Amongb-lactamase producers, a perfect congruency between the different typingmethodswas observed. Surprisingly,
all US and Icelandic b-lactamase-producing isolates were almost indistinguishable, belonged to the major international invasive PFGE clone K/
MLST ST-6, but differed from the four genetically unrelated Israeli b-lactamase-producing clones. Representative strains of different genotypes
produced the TEM-1 enzyme. K. kingae b-lactamase producers exhibit a clear clonal distribution and have dissimilar invasive potential. The
presence of the enzyme in isolates belonging to themajorworldwide invasive clone K/ST-6 highlights the possible spread of b-lactam resistance,
and emphasizes the importance of routine testing of all K. kingae clinical isolates for b-lactamase production.
Keywords: Clones, dissemination, genotypes, Kingella kingae, b-lactamase
Original Submission: 9 December 2013; Revised Submission: 7 April 2014; Accepted: 10 April 2014
Editor: P. Tassios
Article published online: 26 April 2014
Clin Microbiol Infect 2014; 20: O811–O817
10.1111/1469-0691.12648
Corresponding author: S. Bonacorsi, Service de Microbiologie,
Ho^pital Robert-Debre, 48 Boulevard Serurier, 75019 Paris, France
E-mail: stephane.bonacorsi@rdb.aphp.fr
Introduction
b-lactamase production is a survival strategy shared by many
pathogens of respiratory origin in order to colonize and persist
on the human mucosal surfaces. Organisms such as Staphylococ-
cus aureus,Moraxella catarrhalis orHaemophilus inﬂuenzae, which
are frequently carried on the upper respiratory tract, are
repeatedly exposed to antimicrobial drugs that exert a strong
selective pressure upon the resident ﬂora [1], resulting in high
rates of antibiotic resistance. Kingella kingae, an emerging
aetiology of bacteraemia and bone and joint infections in young
children, is also a normal component of the upper respiratory
tract microbiota [2–5]. The prevalence of the organism in the
oropharynx reaches 10–12% in 12- to 24-month-old children
[6], coinciding with the age of increased antibiotic consumption
[7] and enhanced vulnerability to invasive K. kingae infections
[2,3,5]. Although K. kingae is usually susceptible to antibiotics
that are empirically administered to children with suspected
bacteraemia or skeletal system infections, b-lactamase produc-
tion has been sporadically detected in Iceland since 1995 [8,9],
the USA since 1993 [9–11] and Israel since 2001 [12] (Fig. 1).
Typing of K. kingae isolates by molecular methods, such
as multilocus sequence typing (MLST), pulsed-ﬁeld gel
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electrophoresis (PFGE) and single locus polymorphisms of the
rtxA gene encoding the RTX toxin [13] and the por gene that
encodes the bacterial porin [9], has revealed remarkable
genomic heterogeneity in the species. To date, 37 MLST
sequence types (STs) and 74 PFGE clones have been identiﬁed,
as well as 18 rtxA and 11 different por alleles [9,13–15]. Using
these molecular tools, a study was conducted to characterize
b-lactamase-producing strains of K. kingae and investigate the
prevalence of b-lactamase production among isolates from
different geographical origins.
Methods
Source of the Kingella kingae isolates employed in the study
Strains isolated from healthy carriers (n = 447) and patients
(n = 331) with a variety of invasive diseases (bacteraemia,
skeletal system infections and endocarditis) were screened for
b-lactamase production. Geographical origins and periods of
isolation are provided in Table 1. Among b-lactamase pro-
ducers, all the US and Icelandic isolates, as well as the two
invasive and 33 of the 66 carriage strains from Israel were
further characterized by molecular methods. Knowing that
these 66 b-lactamase-producing Israeli isolates derived from
respiratory carriers were previously genotyped by PFGE and
all belonged to only four clones (A, F, T and Ψ), the 33 carriage
b-lactamase producers were randomly selected from 66
representing these four clones [12].
Antibiotic susceptibility testing
b-lactamase production was assessed by the nitroceﬁn method
(Becton Dickinson & Co., Sparks, MD, USA). Minimal inhib-
itory concentrations (MICs) were determined by the E-test
method (BioMerieux, Marcy-l’Etoile, France) on Mueller-Hin-
ton agar with added 5% sheep-blood, as previously described
[16].
Pulsed-ﬁeld gel electrophoresis typing
PFGE typing was performed as previously described
[12,14,15]. Restriction patterns were interpreted according
to the criteria proposed by Tenover et al. [17].
Multilocus sequencing typing
Detailed description of the MLST method has been published
elsewhere [13]. The ST of all examined strains is available on
the Pasteur Institute of Paris website http://www.pasteur.fr/
recherche/genopole/PF8/mlst/Kingella kingae.html.
The genomic relatedness of typeable b-lactamase-producing
organisms and previously characterized K. kingae strains [13]
was investigated by comparing allelic proﬁles using the
FIG. 1. Time-line of the ﬁrst detection of b-lactamase-producing Kingella kingae isolates, their geographical origin and clinical source.
TABLE 1. Prevalence of b-lactamase production among colonizing and invasive Kingella kingae isolates from different
geographical origins
Country Region/city Period
Pharyngeal colonizers Invasive isolates
n b-lactamase producers n b-lactamase producers
Francea Countrywide 1972–2013 NA – 56 0 (0.0%)
Spain Barcelona 1997–2012 1 – 32 0 (0.0%)
Icelandb Reykjavik 1995–2010 NA – 14 4 (28.6%)
Israelc Countrywide 1991–2012 429 66 (15.4%) 190 2 (1.1%)
USAd Countrywide 2003–2012 17 5 (29.4%) 15 3 (20.0%)
Canadae Montreal 2003–2013 NA – 24 0 (0.0%)
NA, not available.
aThese strains were partially characterized by multilocus sequence typing (MLST) in a previous study [13].
bProvided by Dr Hjordis Harðardottir from the Department of Clinical Microbiology, Landspitali University Hospital, Rejkyavik.
cThese strains were partially characterized by pulsed-ﬁeld gel electrophoresis and MLST in previous studies [12,13].
dThirteen invasive and 17 carriage US isolates were provided by the Minnesota State Health Department [11]. Among them, the ﬁve b-lactamase-producing carriage strains and 11
b-lactamase non-producers were collected in a day care centre, where a cluster of invasive K. kingae infections occurred [11] and, thus, were epidemiologically linked. One invasive
isolate each was received from Dr Paul Planet from Columbia University, New York, and Professor Joseph W. St Geme, from the Children’s Hospital of Philadelphia Research
Institute.
eProvided by Dr P. Ovetchkine from Sainte-Justine Hospital, University of Montreal.
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minimum spanning tree method employing the BioNumerics
software (version 7.1, Applied-Maths, Kortrijk, Belgium).
RTX-toxin gene sequencing
Ampliﬁcation, sequencing and polymorphism of the rtxA gene
were previously described [13,18] and rtxA gene alleles
sequences are available in Genbank (accession number from
JQ340459 to JQ340476) [12].
Phylogeny by 16S rRNA gene sequencing
Sequencing of the 16S rRNA gene of several representative
organisms of the K. kingae clone was performed as described
by Weisburg et al. [19]. The relatedness between these
isolates and other species within the Kingella genus (K. oralis
ATCC 51147, K. potus CIP 108935, K. denitriﬁcans ATCC
33394) was expressed as a dendrogram, constructed by the
neighbor-joining method using the MEGA 3.1 software.
Sequencing of the b-lactamase gene (blaTEM)
For the Israeli isolates, ampliﬁcation of the b-lactamase gene
was performed using multiplex PCR, targeting TEM, SHV and
OXA-1-like genes, as previously described [20]. Ampliﬁcation
products were sequenced by a Beckman-Coulter Genomics
instrument (Takeley, Essex, UK) using primers Mul-
tiTSO-T_for and MultiTSO-T_rev as previously described
[20]. The b-lactamase gene of the US and Icelandic isolates has
been previously characterized and published [9].
Porin gene typing
The por gene ampliﬁcation, sequencing and typing were
performed as previously described [9].
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 5.01 for Windows (GraphPad Software, San Diego,
CA, USA). Categorical variables were compared with the
chi-square test or the Fisher’s exact test as appropriate.
Continuous variables were compared with the Mann–Whitney
U-test or Student t-test according to their homogeneity. A
p-value <0.05 was considered signiﬁcant for all comparisons.
Results
Among the total 778 strains (447 isolated from oropharyngeal
swabs and 331 isolated from normal sterile sites), 80 (10.3%)
were b-lactamase producers: four of the 14 (28.6%) Icelandic
invasive isolates, three of the 15 (20.0%) US invasive isolates,
two of 190 (1.1%) Israeli invasive isolates, ﬁve of the 17 (29.4%)
US carrier isolates and 66 of 429 (15.4%) random Israeli
carrier isolates. No French, Spanish or Canadian isolates
(n = 113) were b-lactamase producers (Table 1). Demo-
graphic and clinical data of the patients from whom the
b-lactamase-producing isolates derived are available in Table
S1.
Clonal study
Results of the PFGE, MLST and sequencing of the por and rtxA
genes of the b-lactamase producers are summarized in
Table 2. All the strains could be typed by the different
methods used, except those belonging to PFGE clone T, which
were not typeable by MLST. A perfect congruency between
the different typing methods was observed (Table 2).
The Israeli b-lactamase-producing organisms belonged to
four distinct PFGE clones, namely A, F, T and w, and all isolates
belonging to these clones expressed the enzyme [12].
Interestingly, all US and Icelandic b-lactamase-producing iso-
lates belonged to the same PFGE clone (clone K), MLST ST
(ST-6) (Fig. 2), and harboured the same por allele (por 1) and
two closely related rtxA alleles (rtxA 8 and rtxA 9), but differed
from the four Israeli b-lactamase-producing clones (Table 2).
Fig. 2 depicts the genetic relatedness of the ST of
b-lactamase-producing strains using a minimum spanning tree,
in the context of the previously published STs of the species
[13]. Of note, typeable b-lactamase-producing strains were
grouped into only four ST complexes (STcs), which are
genetically unrelated and scattered all over the tree (Fig. 2).
Interestingly, among clone K/ST-6 isolates, 10 of 12 (83.3%)
b-lactamase producers harboured the rare rtxA allele 9 (see
Table S1), characterized by a triplicate of a 33-base pair (bp)
fragment of the toxin gene, whereas 22 of 24 (91.7%)
TABLE 2. Genotyping results of b-lactamase-producing K. kingae strains derived from different geographical locations
b-lactamase-producing strains
Country of origin PFGE clone n MLST ST MLST STc rtx alleles por alleles b-lactamase gene
Israel A 10 33, 34, 38 34 3, 13 4 TEM-1
Israel F 14 3, 49 3 14 12 TEM-1
Israel T 9 NT NT 17 4, 12 TEM-1
Israel Ψ 2 40 29 4 12 TEM-1
Iceland K 4 6 6 8, 9 1 TEM-1
USA K 8 6 6 8, 9 1 TEM-1
ST, sequence type; STc, sequence type complex; NT, not typeable.
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b-lactamase-negative isolates harboured rtxA alleles 8, 10 or
11, characterized by a duplicate of the 33-bp fragment [13].
Whereas MLST analysis of the b-lactamase producers in this
study identiﬁed three novel STs (ST-38, ST-39 and ST-40;
Fig. 2), it failed to type clone T strains, because only three
housekeeping genes could be ampliﬁed, despite using different
couples of primers. abcZ sequencing found a known allele
(abcZ 8) [13], while adk and cpn60 sequences showed only 83%
identity with the closest K. kingae alleles (data not shown).
Thus, clone T is more distantly related to all other K. kingae
clones described to date, although it harbours the previously
described rtxA 17 allele [13] and the por 12 allele, which is
shared by some other Israeli b-lactamase-producing K. kingae
clones (Tables 2 and S1). In order to assess the genetic
distance, 16S rRNA gene sequences of three clone T isolates
(D2756, PER2744 and Sch169) were determined and com-
pared with that of one representative isolate of different
K. kingae STs (Fig. 3). Phylogenetic analysis indicated that clone
T isolates are genetically divergent from the main K. kingae
population, sharing only 96.9% nucleotide identity with the
sequence of the type strain ATCC 23330 (Fig. 3).
Analysis of the b-lactamase gene sequences for a sample of
17 of 35 Israeli b-lactamase producers revealed that all
harboured the blaTEM gene encoding for the TEM-1 enzyme
(see Table S1), as previously described in US and Icelandic
b-lactamase-producing isolates [9]. Of note, US and Icelandic
producers (belonging to clone K/ST-6), exhibited the same
nucleotide blaTEM sequence (accession number JX855253) [9],
identical to that of the three Israeli clone T isolates studied.
Analysis of the blaTEM sequences of the other Israeli isolates
belonging to clones A, F and Ψ identiﬁed two other alleles with
silent mutations (data not shown) (accession numbers
KF793831 and KF793832).
MIC results
Amoxicillin MICs of b-lactamase producers ranged from
0.25 mg/L to 8 mg/L with MIC50 and MIC90 of 2 mg/L and
4 mg/L, respectively (Fig. 4). Clavulanate restored the antibi-
otic activity and the MICs of the amoxicillin-clavulanate
combination were all ≤0.25 mg/L. Amoxicillin MIC50 of clone
A isolates was signiﬁcantly lower than that of clone F (0.5 mg/L
vs. 2 mg/L, p 0.001) and clone K strains (0.5 mg/L vs. 1 mg/L,
p 0.012) (Fig. 4).
Discussion
The true importance of K. kingae as a human pathogen and its
role in invasive infections of young children is increasingly
being appreciated [2]. However, our current knowledge on
the epidemiology of K. kingae infections and the biological
characteristics of the species remains fragmentary and the
present study is the ﬁrst to reﬂect the situation with a large
number of strains in different countries. Our work suggests
that the prevalence of b-lactamase production in K. kingae
differs widely between countries, ranging from nil in invasive
French, Spanish and Canadian isolates to 20–28% in USA and
Icelandic organisms. Production of b-lactamase has important
FIG. 2. Minimum spanning tree analysis, using BioNumerics Version 7.1, of 142 K. kingae isolates based on allelic proﬁles of six housekeeping genes.
Each circle corresponds to a sequence type (ST). The ST number is given beside the circle, and the size of the circle is proportional to the number of
isolates found with that proﬁle (from one for ST-1 to 34 for ST-6). b-lactamase-producing strains are shown in colour and each colour denotes the
strain’s geographical origin (green, Israel; yellow, USA; pink, Iceland). White circles represent non-b-lactamase-producing strains. Black stripes in
coloured sections indicate carriage isolates, while non-striped coloured sections represent invasive isolates. Grey areas surrounding circles indicate
that these STs belong to the same ST complex. PFGE clones of the b-lactamase-producing strains are noted beside their corresponding ST.
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therapeutic implications because, while most K. kingae infec-
tions run a benign clinical course, the organism may cause
severe skeletal system morbidity [21] and fatal endocarditis
[2], requiring the timely choice of adequate antimicrobial
coverage, pending identiﬁcation and susceptibility results.
The ﬁve b-lactamase-producing clones identiﬁed worldwide
are genetically unrelated, harbour the TEM-1 enzyme, exhibit
noticeable genetic stability over more than a decade, dissem-
inated widely among healthy carriers, and a few have caused
bacteraemia, septic arthritis, osteomyelitis or endocarditis.
This persistent colonization ﬁtness and transmission success
suggests that b-lactamase-producing clones possess a selective
biological advantage. Unexpectedly, none of the 56 French or
33 Spanish K. kingae isolates was a b-lactamase producer,
despite the fact that these countries are among those with the
highest antibiotic consumption in Europe [22]. However, the
conspicuous absence of b-lactamase-producing strains in the
French, Spanish and Canadian collection should be interpreted
with caution because no carriage isolates have been investi-
gated yet, and the number of invasive strains studied is small
and derives from a few geographical regions.
While in Israel b-lactamase production was present in four
distinct and apparently country-speciﬁc clones, a single com-
mon strain was identiﬁed in both Minneapolis and Reykjavik.
The perfect congruency between the results of the MLST that
examines relatively conserved housekeeping genes, the PFGE
FIG. 3. Dendrogram of 16S rRNA gene
sequences (1416 bp) using the
neighbour-joining method (100
bootstraps). Three representative Kingella
kingae isolates belonging to the
non-MLST-typeable clone T, one
representative K. kingae isolate of 14
different STs and one isolate of K. oralis,
K. potus and K. denitriﬁcans species are
presented. *Type strain of the species.
FIG. 4. Distribution of amoxicillin
minimal inhibitory concentrations (MICs)
among 41 b-lactamase-producing strains of
Kingella kingae (eight US, four Icelandic and
29 Israeli strains), belonging to ﬁve distinct
genetic clones. Black, cloneA; black stripes,
clone F; grey, clone K; white, clone T; grey
stripes, clone Ψ.
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that randomly explores the whole genome and the sequencing
of the polymorphic rtxA, por and blaTEM genes makes the
possibility that the observed identity resulted from serendip-
itous convergent evolution highly improbable [13,23]. Rather,
the complete genomic match between b-lactamase-producing
K. kingae strains from these relatively isolated sites located one
ocean apart, suggests a transatlantic crossing, although the
direction (from Iceland to the USA or the other way around)
and the time of the event(s) remain entirely speculative. It is
possible that the dissemination of the clone is related to the
large community of individuals of Icelandic ancestry residing in
Minnesota (Embassy of Iceland: http://www.iceland.is/ice-
land-abroad/us/iceland-and-the-us/icelandic-americans/), and
probably reﬂects frequent population contacts between the
two locations.
In terms of virulence, the b-lactamase-producing clones
show remarkable differences. In a recent study, the four Israeli
clones A, F, T and Ψ collectively comprised 66 of 429 (15.4%)
isolates from healthy pharyngeal carriers but only two of 190
(1.1%) K. kingae isolates derived from patients with deep-site
infections (p <0.001), implying that organisms belonging to
these b-lactamase-producing clones are less invasive than their
non-b-lactamase-producing counterparts [12]. Moreover, it
was previously shown that some K. kingae clones were
commonly carried in the pharynx by asymptomatic children
but were seldom if ever detected in patients with invasive
diseases, and vice versa [14,15]. This suggests a trade-off
between colonization and transmissibility on the one hand, and
virulence on the other, as proposed for Streptococcus pneumo-
niae clones and serotypes [24]. However, the PFGE clone K/
MLST ST-6 strain was found in healthy carriers in Minneapolis
but also in a substantial fraction of patients with clinical
infections in both Minneapolis and Reykjavik, and thus appears
to combine an optimal balance between persisting oropharyn-
geal colonization capability and transmissibility on the one
hand, and invasiveness on the other. Furthermore, this
organism predominated as a carriage strain in Israel, with the
ability to persist up to 4 months [14,25], and was also found to
be an invasive strain, which was signiﬁcantly associated with
childhood bacteraemia [15,26]. Finally, clone K/ST-6 is also
one of the predominant clones in France causing osteoarticular
infections and endocarditis [13]. Detection of the K/ST-6
strain also in the USA and Iceland conﬁrms, on a wider scale,
that it is a truly international clone, although the French and
Israeli versions of the strain lack b-lactamase.
It is possible that acquisition of a plasmid encoding the
TEM-1 b-lactamase further enhances the strain’s biological
success by becoming resistant to antibiotics and, therefore, the
discovery of b-lactamase in clone K/ST-6 may have a major
clinical impact and herald further dissemination of TEM-1
b-lactamases in K. kingae. Interestingly, all isolates belonging to
this clone examined so far exhibited a rare genetic trait,
consisting of a 33-bp repeat of a fraction of the rtxA gene
sequence (rtxA 8, 9, 10 and 11 alleles) [13]. Whether this
repetition in a gene encoding for a putative virulence factor
[18,27] contributes to the clone’s invasiveness remains spec-
ulative. On the other hand, a 33-bp repetition occurred also in
clone T (rtxA 17 allele), which appears as a common but
exclusively carriage clone, suggesting that it may also play a
role in the persistence of these organisms on the upper
respiratory epithelium. However, 16S rRNA sequencing
showed that this clone is more distantly related to other
K. kingae isolates, and may represent a subspecies devoid of
invasiveness.
Finally, analysis of amoxicillin susceptibility data revealed
that K. kingae b-lactamase confers a low-level resistance to
penicillin drugs, with MIC values lower than those observed
among H. inﬂuenzae or M. catarrhalis b-lactamase producers,
which exhibit MIC50 and MIC90 between 4 and 8 mg/L [28].
Furthermore, a difference between MICs50 was observed
between the different clones, clone A harbouring the lowest
MICs. As the aminoacid sequences of TEM-1 enzymes were
identical, the possibility that other genetic determinants
contribute to modulate the expression K. kingae b-lactamase
is suggested. Importantly, in several strains, amoxicillin MICs
did not signiﬁcantly differ from those of b-lactamase non-pro-
ducers [16], emphasizing the need for routine testing for the
presence of the enzyme by the sensitive nitroceﬁn method.
In summary, the results of the present study indicate that
b-lactamase production in K. kingae exhibits a clear clonal
distribution and enzyme-producing organisms have dissimilar
invasive potential. Although the prevalence of the trait differs
between countries, evidence of the wide geographical dissem-
ination of the invasive K/ST-6 clone highlights the need for
international collaboration to monitor its spread, as well as the
possible emergence of novel antibiotic-resistant clones. Because
information on the local prevalence of b-lactamase production
by K. kingae is still limited and fragmentary, as a measure of
caution, we believe that routine testing of all invasive isolates for
b-lactamase production would be beneﬁcial.
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